Mazumdar Claire, CEO of Bicara Therapeutics Inc. ($BCAX), sold shares on the open market eight times in the last 365 days, totaling $2.56 million. Her most recent sale occurred on March 9, 2026. These BCAX insider sales rank 3,008th among 11,678 individual insiders in our database, where the average is $8.6 million across about 6.4 transactions per insider. Claire made no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 20, 2026 | Bicara Therapeutics Inc. | $BCAX | Mazumdar Claire | Chief Executive Officer | M | Stock Option (Right to Buy) | 1596 | $0.00 | 176,107.0000 | 54,563,864 | 0.90% | 0.00% |
| March 19, 2026 | Bicara Therapeutics Inc. | $BCAX | Mazumdar Claire | Chief Executive Officer | M | Common Stock | 6905 | $3.79 | 346,297.0000 | 54,563,864 | 2.03% | 0.01% |
| March 19, 2026 | Bicara Therapeutics Inc. | $BCAX | Mazumdar Claire | Chief Executive Officer | S | Common Stock | 6905 | $18.78 | 339,392.0000 | 54,563,864 | 1.99% | 0.01% |
| March 20, 2026 | Bicara Therapeutics Inc. | $BCAX | Mazumdar Claire | Chief Executive Officer | M | Common Stock | 1596 | $3.79 | 340,988.0000 | 54,563,864 | 0.47% | 0.00% |
| March 18, 2026 | Bicara Therapeutics Inc. | $BCAX | Mazumdar Claire | Chief Executive Officer | M | Common Stock | 6499 | $3.79 | 345,891.0000 | 54,563,864 | 1.91% | 0.01% |
| March 18, 2026 | Bicara Therapeutics Inc. | $BCAX | Mazumdar Claire | Chief Executive Officer | S | Common Stock | 6499 | $18.84 | 339,392.0000 | 54,563,864 | 1.88% | 0.01% |
| March 20, 2026 | Bicara Therapeutics Inc. | $BCAX | Mazumdar Claire | Chief Executive Officer | S | Common Stock | 1596 | $18.95 | 339,392.0000 | 54,563,864 | 0.47% | 0.00% |
| March 18, 2026 | Bicara Therapeutics Inc. | $BCAX | Mazumdar Claire | Chief Executive Officer | M | Stock Option (Right to Buy) | 6499 | $0.00 | 184,608.0000 | 54,563,864 | 3.40% | 0.01% |
| March 19, 2026 | Bicara Therapeutics Inc. | $BCAX | Mazumdar Claire | Chief Executive Officer | M | Stock Option (Right to Buy) | 6905 | $0.00 | 177,703.0000 | 54,563,864 | 3.74% | 0.01% |
| March 9, 2026 | Bicara Therapeutics Inc. | $BCAX | Mazumdar Claire | Chief Executive Officer | S | Common Stock | 36766 | $19.17 | 339,392.0000 | 54,563,864 | 9.77% | 0.07% |
| March 9, 2026 | Bicara Therapeutics Inc. | $BCAX | Mazumdar Claire | Chief Executive Officer | M | Stock Option (Right to Buy) | 36766 | $0.00 | 191,107.0000 | 54,563,864 | 16.13% | 0.07% |
| March 9, 2026 | Bicara Therapeutics Inc. | $BCAX | Mazumdar Claire | Chief Executive Officer | M | Common Stock | 36766 | $3.79 | 376,158.0000 | 54,563,864 | 10.83% | 0.07% |
| March 4, 2026 | Bicara Therapeutics Inc. | $BCAX | Mazumdar Claire | Chief Executive Officer | S | Common Stock | 2631 | $18.73 | 339,392.0000 | 54,563,864 | 0.77% | 0.00% |
| March 5, 2026 | Bicara Therapeutics Inc. | $BCAX | Mazumdar Claire | Chief Executive Officer | S | Common Stock | 1786 | $18.74 | 339,392.0000 | 54,563,864 | 0.52% | 0.00% |
| March 6, 2026 | Bicara Therapeutics Inc. | $BCAX | Mazumdar Claire | Chief Executive Officer | M | Common Stock | 3817 | $3.79 | 343,209.0000 | 54,563,864 | 1.12% | 0.01% |
| March 6, 2026 | Bicara Therapeutics Inc. | $BCAX | Mazumdar Claire | Chief Executive Officer | M | Stock Option (Right to Buy) | 3817 | $0.00 | 227,873.0000 | 54,563,864 | 1.65% | 0.01% |
| March 5, 2026 | Bicara Therapeutics Inc. | $BCAX | Mazumdar Claire | Chief Executive Officer | M | Stock Option (Right to Buy) | 1786 | $0.00 | 231,690.0000 | 54,563,864 | 0.76% | 0.00% |
| March 4, 2026 | Bicara Therapeutics Inc. | $BCAX | Mazumdar Claire | Chief Executive Officer | M | Stock Option (Right to Buy) | 2631 | $0.00 | 233,476.0000 | 54,563,864 | 1.11% | 0.00% |
| March 6, 2026 | Bicara Therapeutics Inc. | $BCAX | Mazumdar Claire | Chief Executive Officer | S | Common Stock | 3817 | $18.75 | 339,392.0000 | 54,563,864 | 1.11% | 0.01% |
| March 4, 2026 | Bicara Therapeutics Inc. | $BCAX | Mazumdar Claire | Chief Executive Officer | M | Common Stock | 2631 | $3.79 | 342,023.0000 | 54,563,864 | 0.78% | 0.00% |
| March 5, 2026 | Bicara Therapeutics Inc. | $BCAX | Mazumdar Claire | Chief Executive Officer | M | Common Stock | 1786 | $3.79 | 341,178.0000 | 54,563,864 | 0.53% | 0.00% |
| Feb. 2, 2026 | Bicara Therapeutics Inc. | $BCAX | Mazumdar Claire | Chief Executive Officer | A | Stock Option (Right to Buy) | 450000 | $0.00 | 450,000.0000 | 54,563,864 | 9999.99% | 0.82% |
| Dec. 16, 2025 | Bicara Therapeutics Inc. | $BCAX | Mazumdar Claire | Chief Executive Officer | M | Common Stock | 29500 | $5.45 | 339,392.0000 | 54,563,864 | 9.52% | 0.05% |
| Dec. 16, 2025 | Bicara Therapeutics Inc. | $BCAX | Mazumdar Claire | Chief Executive Officer | M | Stock Option (Right to Buy) | 29500 | $0.00 | 565,512.0000 | 54,563,864 | 4.96% | 0.05% |
| Nov. 24, 2025 | Bicara Therapeutics Inc. | $BCAX | Mazumdar Claire | Chief Executive Officer | M | Stock Option (Right to Buy) | 41163 | $0.00 | 236,107.0000 | 54,563,864 | 14.85% | 0.08% |
| Nov. 24, 2025 | Bicara Therapeutics Inc. | $BCAX | Mazumdar Claire | Chief Executive Officer | M | Common Stock | 41163 | $3.79 | 351,055.0000 | 54,563,864 | 13.28% | 0.08% |
| Nov. 24, 2025 | Bicara Therapeutics Inc. | $BCAX | Mazumdar Claire | Chief Executive Officer | S | Common Stock | 41163 | $18.86 | 309,892.0000 | 54,563,864 | 11.73% | 0.08% |
| Oct. 16, 2025 | Bicara Therapeutics Inc. | $BCAX | Mazumdar Claire | Chief Executive Officer | M | Stock Option (Right to Buy) | 24103 | $0.00 | 277,270.0000 | 54,563,864 | 8.00% | 0.04% |
| Oct. 16, 2025 | Bicara Therapeutics Inc. | $BCAX | Mazumdar Claire | Chief Executive Officer | M | Common Stock | 24103 | $3.79 | 333,995.0000 | 54,563,864 | 7.78% | 0.04% |
| Oct. 16, 2025 | Bicara Therapeutics Inc. | $BCAX | Mazumdar Claire | Chief Executive Officer | S | Common Stock | 24103 | $18.83 | 309,892.0000 | 54,563,864 | 7.22% | 0.04% |
| Oct. 15, 2025 | Bicara Therapeutics Inc. | $BCAX | Mazumdar Claire | Chief Executive Officer | S | Common Stock | 13289 | $18.84 | 309,892.0000 | 54,563,864 | 4.11% | 0.02% |
| Oct. 15, 2025 | Bicara Therapeutics Inc. | $BCAX | Mazumdar Claire | Chief Executive Officer | M | Stock Option (Right to Buy) | 13289 | $0.00 | 301,373.0000 | 54,563,864 | 4.22% | 0.02% |
| Oct. 13, 2025 | Bicara Therapeutics Inc. | $BCAX | Mazumdar Claire | Chief Executive Officer | M | Stock Option (Right to Buy) | 11445 | $0.00 | 314,662.0000 | 54,563,864 | 3.51% | 0.02% |
| Oct. 13, 2025 | Bicara Therapeutics Inc. | $BCAX | Mazumdar Claire | Chief Executive Officer | M | Common Stock | 11445 | $3.79 | 321,337.0000 | 54,563,864 | 3.69% | 0.02% |
| Oct. 15, 2025 | Bicara Therapeutics Inc. | $BCAX | Mazumdar Claire | Chief Executive Officer | M | Common Stock | 13289 | $3.79 | 323,181.0000 | 54,563,864 | 4.29% | 0.02% |
| Oct. 13, 2025 | Bicara Therapeutics Inc. | $BCAX | Mazumdar Claire | Chief Executive Officer | S | Common Stock | 11445 | $18.92 | 309,892.0000 | 54,563,864 | 3.56% | 0.02% |
| June 9, 2025 | Relay Therapeutics, Inc. | $RLAY | Mazumdar Claire | Not found | A | Stock Option (Right to Buy) | 421241 | $0.00 | 421,241.0000 | 169,521,849 | 9999.99% | 0.25% |